NEPT - ネプチュ―ン・テクノロジ―ズ・アンド・バイオリソ―シズ (Neptune Wellness Solutions Inc.) ネプチュ―ン・テクノロジ―ズ・アンド・バイオリソ―シズ

 NEPTのチャート


 NEPTの企業情報

symbol NEPT
会社名 Neptune Technologies_Bioresources Inc (ネプチュ―ン・テクノロジ―ズ・アンド・バイオリソ―シズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種    一般消費財(Consumer Products)
概要 事業概要 --   ネプチュ―ン・テクノロジ―ズ・アンド・バイオリソ―シズは、カナダの栄養医薬品会社。栄養補助食品、機能性食品、化粧品の研究、開発、製造、販売に従事。植物や魚油によるオメガ3系脂肪酸とは異なる南極オキアミ(南極海に生息する甲殻類)から抽出した独自のオメガ3製品などを販売している。本社は、ケベック州ラバル。   Neptune Wellness Solutions, Inc. is a diversified health and wellness company. It engages in building a broad portfolio of quality, affordable consumer products in response to long-term secular trends and market demand for natural, plant-based, sustainable and purpose-driven lifestyle brands. The company utilizes a flexible, cost efficient manufacturing and supply chain infrastructure that can be scaled up and down or into adjacent product categories to identify opportunities, quickly adapt to consumer preferences and demand, and bring new products to market through its mass retail partners and e-commerce channels. Neptune Wellness Solutions was founded by Henri Harland on October 9, 1998 and is headquartered in Laval, Canada.
本社所在地 545 Promenade du Centropolis Suite 100 Laval Quebec H7T 0A3 CAN
代表者氏名
代表者役職名
電話番号
設立年月日 36069
市場名 NASDAQ Small Cap
ipoyear ―年
従業員数 61人
url www.neptunebiotech.com
nasdaq_url https://www.nasdaq.com/symbol/nept
adr_tso
EBITDA EBITDA ー
終値(lastsale) 4.31
時価総額(marketcap) 342726196.09
時価総額 時価総額 ―
売上高 売上高 --
企業価値(EV) 企業価値(EV) ー
当期純利益 当期純利益 --
決算概要 決算概要 --

 NEPTのテクニカル分析


 NEPTのニュース

   Earnings Preview: Neptune Technologies (NEPT) Q4 Earnings Expected to Decline  2020/06/03 16:30:07 Zacks Investment Research
Neptune Tech (NEPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
   Neptune Technologies (NEPT) Reports Break-Even Earnings for Q3  2020/02/13 12:45:04 Zacks Investment Research
Neptune Tech (NEPT) delivered earnings and revenue surprises of 100.00% and -2.78%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
   The Week In Cannabis: Stocks Fall On Poor Earnings, More Americans Support Legalization  2019/11/15 22:12:28 Benzinga
Two-thirds of Americans say the use of marijuana should be legal, reflecting a considerable surge over the past decade.. Two-thirds of Americans say the use of marijuana should be legal, reflecting a steady increase over the past decade https://t.co/QoMXjiaUYk pic.twitter.com/V4vLqY3r9f — Pew Research Fact Tank (@FactTank) November 14, 2019 GW Pharmaceuticals PLC (NASDAQ: GWPH ) announced two of its medicines have been recommended by the U.K.’s National Institute for Health and Care Excellence to receive routine reimbursement from the National Health Service. Epidiolex, known as Epidyolex in Europe, and Sativex were approved by the NHS for the treatment of epilepsy and multiple sclerosis, respectively. These were probably the most upbeat news items in the cannabis and hemp world this week. The following companies disappointed analysts and investors with their quarterly results and/or guidance (see full coverage for all of these earnings reports in our Cannabis Earnings Portal ): Canopy Growth Corp (NYSE: CGC ) Neptune Wellness Solutions Inc.
   Neptune Wellness Falls On Higher Quarterly Net Loss, Announces Hemp-Derived CBD Deal  2019/11/11 15:41:19 Benzinga Feeds
Neptune Wellness Solutions Inc. (NASDAQ: NEPT ) (TSX: NEPT) reported second-quarter revenue of CA$6.51 million ($4.9 million) on Monday and announced a partnership with International Flavors & Fragrances Inc. (NYSE: IFF ). The second-quarter revenue of CA$6.51 million was lower than the CA$7.07 million in revenue posted in the same period of 2018. The company also posted a quarterly net loss of CA$20.78 million versus a net loss of CA$3.05 million in the corresponding quarter of the prior year. Its adjusted EBITDA was a loss of CA$4.58 million, which is by CA$3.35 million lower than in the second quarter of 2018. Neptune also noted recent milestones such as the acquisition of SugarLeaf assets, which included the CBD consumer brand Forest Remedies; and its entrance into a strategic partnership … Full story available on Benzinga.com
   Neptune Technologies (NEPT) Reports Q2 Loss, Lags Revenue Estimates  2019/11/11 13:25:02 Zacks Investment Research
Neptune Tech (NEPT) delivered earnings and revenue surprises of -325.00% and -23.16%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
   Earnings Preview: Neptune Technologies (NEPT) Q4 Earnings Expected to Decline  2020/06/03 16:30:07 Zacks Investment Research
Neptune Tech (NEPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
   Neptune Technologies (NEPT) Reports Break-Even Earnings for Q3  2020/02/13 12:45:04 Zacks Investment Research
Neptune Tech (NEPT) delivered earnings and revenue surprises of 100.00% and -2.78%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
   The Week In Cannabis: Stocks Fall On Poor Earnings, More Americans Support Legalization  2019/11/15 22:12:28 Benzinga
Two-thirds of Americans say the use of marijuana should be legal, reflecting a considerable surge over the past decade.. Two-thirds of Americans say the use of marijuana should be legal, reflecting a steady increase over the past decade https://t.co/QoMXjiaUYk pic.twitter.com/V4vLqY3r9f — Pew Research Fact Tank (@FactTank) November 14, 2019 GW Pharmaceuticals PLC (NASDAQ: GWPH ) announced two of its medicines have been recommended by the U.K.’s National Institute for Health and Care Excellence to receive routine reimbursement from the National Health Service. Epidiolex, known as Epidyolex in Europe, and Sativex were approved by the NHS for the treatment of epilepsy and multiple sclerosis, respectively. These were probably the most upbeat news items in the cannabis and hemp world this week. The following companies disappointed analysts and investors with their quarterly results and/or guidance (see full coverage for all of these earnings reports in our Cannabis Earnings Portal ): Canopy Growth Corp (NYSE: CGC ) Neptune Wellness Solutions Inc.
   Neptune Wellness Falls On Higher Quarterly Net Loss, Announces Hemp-Derived CBD Deal  2019/11/11 15:41:19 Benzinga Feeds
Neptune Wellness Solutions Inc. (NASDAQ: NEPT ) (TSX: NEPT) reported second-quarter revenue of CA$6.51 million ($4.9 million) on Monday and announced a partnership with International Flavors & Fragrances Inc. (NYSE: IFF ). The second-quarter revenue of CA$6.51 million was lower than the CA$7.07 million in revenue posted in the same period of 2018. The company also posted a quarterly net loss of CA$20.78 million versus a net loss of CA$3.05 million in the corresponding quarter of the prior year. Its adjusted EBITDA was a loss of CA$4.58 million, which is by CA$3.35 million lower than in the second quarter of 2018. Neptune also noted recent milestones such as the acquisition of SugarLeaf assets, which included the CBD consumer brand Forest Remedies; and its entrance into a strategic partnership … Full story available on Benzinga.com
   Neptune Technologies (NEPT) Reports Q2 Loss, Lags Revenue Estimates  2019/11/11 13:25:02 Zacks Investment Research
Neptune Tech (NEPT) delivered earnings and revenue surprises of -325.00% and -23.16%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
   Earnings Preview: Neptune Technologies (NEPT) Q4 Earnings Expected to Decline  2020/06/03 16:30:07 Zacks Investment Research
Neptune Tech (NEPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
   Neptune Technologies (NEPT) Reports Break-Even Earnings for Q3  2020/02/13 12:45:04 Zacks Investment Research
Neptune Tech (NEPT) delivered earnings and revenue surprises of 100.00% and -2.78%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
   The Week In Cannabis: Stocks Fall On Poor Earnings, More Americans Support Legalization  2019/11/15 22:12:28 Benzinga
Two-thirds of Americans say the use of marijuana should be legal, reflecting a considerable surge over the past decade.. Two-thirds of Americans say the use of marijuana should be legal, reflecting a steady increase over the past decade https://t.co/QoMXjiaUYk pic.twitter.com/V4vLqY3r9f — Pew Research Fact Tank (@FactTank) November 14, 2019 GW Pharmaceuticals PLC (NASDAQ: GWPH ) announced two of its medicines have been recommended by the U.K.’s National Institute for Health and Care Excellence to receive routine reimbursement from the National Health Service. Epidiolex, known as Epidyolex in Europe, and Sativex were approved by the NHS for the treatment of epilepsy and multiple sclerosis, respectively. These were probably the most upbeat news items in the cannabis and hemp world this week. The following companies disappointed analysts and investors with their quarterly results and/or guidance (see full coverage for all of these earnings reports in our Cannabis Earnings Portal ): Canopy Growth Corp (NYSE: CGC ) Neptune Wellness Solutions Inc.
   Neptune Wellness Falls On Higher Quarterly Net Loss, Announces Hemp-Derived CBD Deal  2019/11/11 15:41:19 Benzinga Feeds
Neptune Wellness Solutions Inc. (NASDAQ: NEPT ) (TSX: NEPT) reported second-quarter revenue of CA$6.51 million ($4.9 million) on Monday and announced a partnership with International Flavors & Fragrances Inc. (NYSE: IFF ). The second-quarter revenue of CA$6.51 million was lower than the CA$7.07 million in revenue posted in the same period of 2018. The company also posted a quarterly net loss of CA$20.78 million versus a net loss of CA$3.05 million in the corresponding quarter of the prior year. Its adjusted EBITDA was a loss of CA$4.58 million, which is by CA$3.35 million lower than in the second quarter of 2018. Neptune also noted recent milestones such as the acquisition of SugarLeaf assets, which included the CBD consumer brand Forest Remedies; and its entrance into a strategic partnership … Full story available on Benzinga.com
   Neptune Technologies (NEPT) Reports Q2 Loss, Lags Revenue Estimates  2019/11/11 13:25:02 Zacks Investment Research
Neptune Tech (NEPT) delivered earnings and revenue surprises of -325.00% and -23.16%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

 関連キーワード  (― 米国株 ネプチュ―ン・テクノロジ―ズ・アンド・バイオリソ―シズ NEPT Neptune Wellness Solutions Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)